Overexpression of cyclophilin A rescued HCV replication in the presence of cyclosporin A. Conclusions: These findings suggest several cyclophilins are essential host factors for HCV RNA replication. Thus potent cyclophilin inhibitors have the potential to be anti-HCV drugs. Background/Aims: Hepatitis C Virus (HCV) genotypes 1-6 have a worldwide distribution. Types 1a and 1b are predominant in Northern Europe and North America, and in Southern and Eastern Europe and Japan, respectively. Type 3 is endemic in south Asia and is variably distributed in different countries. Genotype 4 in Egypt, genotype 5 in Central and South America and genotype 6 is common in China, Japan and South East Asia. In Pakistan 3a is the commonest genotype, which is associated with the most favorable outcome regarding end treatment response and sustained virological response after 24 weeks of therapy. The aim of this study is to find out HCV Genotypes in newly diagnosed chronic hepatitis C patients. Methods: This observational study was conducted in chronic hepatitis C patients. All patients had raised ALT levels for last 06 months, had positive polymerase chain reaction (PCR) for HCV RNA by real time method and liver biopsy was done in all patients under National program for prevention and control of hepatitis during year 2006 -2007. Genotyping was done on Roche Genotyping Kit. Data was analyzed by SPSS 13.0 Results: Out of 164 patients, 85.9% (n=141) were genotype 3a. 6.1% (n=10) were genotype 3b. 3.0% (n=5) were genotype 1a. n= 01 had genotype 1b. 4.2% (n= 7) had mixed genotype (3a,3b/1a,1b,3a,3b). Conclusion: Majority (85.9%) of chronic hepatitis C patients were genotype 3a which is associated with favorable outcome after 24 weeks of interferon and ribavirin therapy and only 3.0% had genotype 1a in this cohort.